Memorial Sloan Kettering Cancer Center
The world's top-ranked cancer hospital, home of MSK-IMPACT sequencing, the dostarlimab rectal cancer study, and CAR-T pioneers.
Overview
Memorial Sloan Kettering Cancer Center is a New York cancer centre founded in 1884, NCI-designated as comprehensive and ranked first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology, which makes it the reference point against which other cancer hospitals are measured. Its firsts include MSK-IMPACT, an FDA-authorised tumour sequencing panel that feeds OncoKB and cBioPortal, co-development of CD19 CAR-T cell therapy with Sadelain's group, the dostarlimab study in mismatch-repair-deficient rectal cancer led by Andrea Cercek, and the Paige AI digital pathology spin-out. It runs one of the largest oncology trial portfolios in the United States. The open question for a centre this large is how quickly its knowledge reaches practice elsewhere, a bottleneck Nuclide tracks explicitly. Its people and trials pages are the best way into the detail.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to Memorial Sloan Kettering Cancer Center, including child institutions. 5,259 works · 96,089 citations · 68% open access · 14% clinical trials · 1% reviews.
- Eileen Mary O'Reilly250 works
- Miguel‐Angel Perales200 works
- Maria Lia Palomba143 works
- Roni Shouval142 works
- Gunjan L. Shah138 works
- Jae H. Park135 works
- Michael Scordo118 works
- Charles M. Rudin117 works
- Gilles Salles113 works
- Julio García‐Aguilar112 works
- MSK-IMPACT / OncoKB
- CAR-T (Sadelain)
- dMMR rectal organ preservation
- Paige AI
- Radiopharmaceutical development
A nuclear medicine doctor who runs the molecular imaging service at Memorial Sloan Kettering and has spent years studying how PET scans taken partway through chemotherapy for lymphoma can predict which patients need more or less treatment.
Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.
An Italian-trained nuclear medicine doctor who helped develop the lutetium-177 dotatate treatment for neuroendocrine tumours and now leads targeted radionuclide therapy at Memorial Sloan Kettering in New York.
Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.
A nuclear medicine doctor who spent 25 years at Memorial Sloan Kettering developing radioactive antibody treatments, including therapies for children with neuroblastoma, before moving to lead nuclear medicine at UPMC Hillman Cancer Center in 2025.
Similar pages
not linked directly; found by shared links- InstitutionMD Anderson Cancer Center
Shares National Cancer Institute (NIH), Diffuse large B-cell lymphoma, Renal cell carcinoma, Small-cell lung cancer.
- InstitutionDana-Farber Brigham Cancer Center
Shares National Cancer Institute (NIH), Neuroblastoma (paediatric), Diffuse large B-cell lymphoma, Renal cell carcinoma.
- CompanyBristol Myers Squibb
Shares Diffuse large B-cell lymphoma, Renal cell carcinoma, Small-cell lung cancer, Hepatocellular carcinoma.
- InstitutionMayo Clinic
Shares National Cancer Institute (NIH), Diffuse large B-cell lymphoma, Hepatocellular carcinoma.
- CompanyMerck & Co. (MSD)
Shares Diffuse large B-cell lymphoma, Renal cell carcinoma, Small-cell lung cancer, Hepatocellular carcinoma.
- AgentSorafenib
Shares Renal cell carcinoma, Thyroid cancer, Hepatocellular carcinoma.
- AgentCabozantinib
Shares Renal cell carcinoma, Thyroid cancer, Hepatocellular carcinoma, Neuroendocrine tumours.
- InstitutionKing Faisal Specialist Hospital and Research Centre